Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of BAT4306F in B-cell Non-Hodgkin's Lymphoma
NCT04152148Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Sep 2018
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT4306F in B-cell non-Hodgkin lymphoma (4 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 4 weeks, Maximum tolerated dose at 4 weeks and 4 more. Started Sep 2018; status: completed.
02
Drugs
BAT4306F
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04152148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152148.